

# BC PHARMACARE NEWSLETTER

Edition 20-016  
September 1, 2020



## In this edition

BENEFITS .....	1
Publicly Funded Vaccines: Seasonal Influenza .....	1
YOUR VOICE: PATIENT INPUT NEEDED FOR DRUG DECISIONS .....	2

## BENEFITS

### Publicly Funded Vaccines: Seasonal Influenza

During the 2020-2021 influenza season, the following vaccines will be covered for eligible residents from September 1, 2020, to June 1, 2021. For information about when supplies will be available in your community, consult your local health unit or health authority.

PIN	VACCINE
66128073	Fluzone® Quadrivalent
66124765	Fluviral®
66124873	Agriflu®
66124872	Fluad®
66128275	Fluzone® High-Dose (trivalent)
66128276	FluMist® Quadrivalent*
66127296	Influsplit® Tetra

\*PharmaCare covers a \$10 pharmacist administration fee for FluMist.

More information is available at [Vaccine Resources for Pharmacists](#).



The PharmaCare Newsletter is published by the Pharmaceutical Services Division to provide information to British Columbia's health care providers.

The use of PharmaNet is not intended as a substitute for professional judgment. Information on PharmaNet is not exhaustive and cannot be relied upon as complete. The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.

[www.gov.bc.ca/pharmacarepharmacists](http://www.gov.bc.ca/pharmacarepharmacists) | [www.gov.bc.ca/pharmacareprescribers](http://www.gov.bc.ca/pharmacareprescribers) | [www.gov.bc.ca/pharmacaredeviceproviders](http://www.gov.bc.ca/pharmacaredeviceproviders)

## YOUR VOICE: PATIENT INPUT NEEDED FOR DRUG DECISIONS

The feedback and experiences of patients, caregivers, and patient groups are integral to [B.C.'s drug review process](#).

The Ministry depends on pharmacies and practitioners to help connect patients and their caregivers with opportunities to provide input. If you have a patient who is currently taking one of the drugs under review or who has the condition the new drug treats, please encourage them to visit [www.gov.bc.ca/BCyourvoice](http://www.gov.bc.ca/BCyourvoice).

<b>DRUG</b>	voretigene neparvovec (Luxturna®)
<b>INDICATION</b>	inherited retinal dystrophy (IRD)
<b>INPUT WINDOW</b>	August 26–September 23, 2020

<b>DRUG</b>	etanercept biosimilar (Erelzi®)
<b>INDICATION</b>	plaque psoriasis
<b>INPUT WINDOW</b>	August 26–September 23, 2020